In a phase 1/2 study, researchers evaluated subcutaneous teclistamab, a CD3×BCMA bispecific T-cell–redirecting antibody, in heavily pretreated relapsed/refractory multiple myeloma. Patients (n=165) had received at least 3 prior lines with exposure to an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody (78% triple-class refractory; median 5 prior lines).
